TrialJournal of the National Cancer Institute2026

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25).

Florence Joly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.